Renovaro (NASDAQ:RENB) Shares Up 6.5% – Still a Buy?

Renovaro Inc. (NASDAQ:RENB)’s stock price was up 6.5% during mid-day trading on Wednesday . The company traded as high as $0.55 and last traded at $0.50. Approximately 450,750 shares were traded during trading, a decline of 16% from the average daily volume of 535,915 shares. The stock had previously closed at $0.47.

Renovaro Trading Up 6.5 %

The firm has a market cap of $79.96 million, a PE ratio of -0.52 and a beta of 0.55. The business has a fifty day moving average of $0.55 and a 200-day moving average of $0.93.

Renovaro (NASDAQ:RENB) last issued its quarterly earnings data on Thursday, October 10th. The company reported ($0.45) earnings per share (EPS) for the quarter.

Institutional Trading of Renovaro

A number of hedge funds have recently bought and sold shares of the company. Barclays PLC grew its position in Renovaro by 315.7% during the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after acquiring an additional 52,804 shares during the last quarter. State Street Corp increased its position in Renovaro by 3.8% during the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after purchasing an additional 48,114 shares during the period. Rhumbline Advisers bought a new position in Renovaro in the second quarter worth about $79,000. Bank of New York Mellon Corp bought a new position in shares of Renovaro in the 2nd quarter worth approximately $220,000. Finally, Tidal Investments LLC purchased a new position in Renovaro during the first quarter valued at $98,000. Institutional investors own 71.41% of the company’s stock.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.